PMV Pharmaceuticals Inc
NASDAQ:PMVP
PMV Pharmaceuticals Inc
NASDAQ:PMVP
Price:
1.47
USD
-2%
Market Cap:
$78.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
PMV Pharmaceuticals Inc
NASDAQ:PMVP
|
US |
|
DigiTouch SpA
MIL:DGT
|
IT |
|
O
|
Origin Property PCL
SET:ORI
|
TH |
|
Altech Corp
TSE:4641
|
JP |
|
J
|
Joinn Laboratories China Co Ltd
SSE:603127
|
CN |
|
IDW Media Holdings Inc
OTC:IDWM
|
US |
|
Iberdrola SA
MAD:IBE
|
ES |
|
Atlantic Sapphire ASA
OTC:AASZF
|
NO |
|
R
|
Readboy Education Holding Co Ltd
HKEX:2385
|
CN |
|
R
|
ReWay Group SpA
MIL:RWY
|
IT |
|
J
|
Jastrzebska Spolka Weglowa SA
WSE:JSW
|
PL |
|
China Unicom Hong Kong Ltd
HKEX:762
|
HK |
|
Daqo New Energy Corp
NYSE:DQ
|
CN |
|
Aspen Aerogels Inc
NYSE:ASPN
|
US |
|
O
|
Oncolytics Biotech Inc
NASDAQ:ONCY
|
CA |
|
Equinor ASA
OSE:EQNR
|
NO |
|
G
|
Gujarat Pipavav Port Ltd
NSE:GPPL
|
IN |
|
Leoch International Technology Ltd
HKEX:842
|
CN |
Relative Value
The Relative Value of one
PMVP
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1.47 USD,
PMV Pharmaceuticals Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PMVP Relative Value
HIDDEN
Multiples Across Competitors
PMVP Competitors Multiples
PMV Pharmaceuticals Inc Competitors
PMV Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
PMV Pharmaceuticals Inc
NASDAQ:PMVP
|
78.4m USD | 0 | -1 | 0.4 | 0.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86 | 14.3 | 19.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20.1 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.3 | 12.8 | 14.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 10.9 | 129 | 72.1 | 80.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
